In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a sharper eye and be ready for the amylin‑based therapies that may be on the horizon.
In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.
In this CME Outfitters Snack, expert faculty will demonstrate evidence‑based use of GnRH antagonists within non‑surgical management, including patient selection, dosing, monitoring, and positioning. Faculty will model how to individualize therapy by integrating patient goals, clinical characteristics, and current evidence into tailored medical plans that strengthen therapeutic sequencing and shared decision‑making.
In this installment of a CME Snack series, expert faculty will discuss the application of practical strategies for acquiring and administering ATTs and conducting patient monitoring during therapy.
In this installment of a CME Outfitters Snack series on AD, expert faculty discuss how to better engage in communication with patients and other HCPs to facilitate optimized SDM regarding ATTs.
In this installment of a CMEO Snack series, expert faculty will synthesize emerging evidence to enable clinicians to critically appraise the appropriateness and clinical application of ATTs for patients with early symptomatic Alzheimer’s disease.